Health Care Research and Customer Insights

Our Objective Insights. Your Strategic Advantage.

Darwin Research Group delivers strategic intelligence and deep executive insights that guide health care leaders to make confident decisions. Our expert knowledge of the ever-evolving health care landscape gives you the perspective you need to stay ahead.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

vaccine

cdc

February 16, 2026

Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

Eli Lilly

Novo Nordisk

February 9, 2026

Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

unitedhealth

gsk

February 2, 2026

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Providing insights for the most prominent leaders in health care.

Our Services

We’re here to serve you.

We provide the intelligence and insight health care leaders need to move beyond transactions and build a more connected, strategic approach to growth.

Explore all Services

Consulting & Strategic Counsel

We work with CEOs and other senior executives and tailor strategic intelligence services to the specific needs of the highest levels in an organization. Darwin CEO John Marchica leads this effort, providing his analysis and guidance directly to the client.

Learn More

Customer Intelligence, Data, & Profiles

We develop each health system profile profile with rigor and strategic intent, and complete it with rich, actionable insights across all facets of the organization.

Learn More

Inside Access To Research & Data

When our clients need to sharpen their business, marketing, market access, and sales strategies, they rely on the customer profiles we develop to inform and enhance their decision making, using them over and over again as a vital “go to” resource.

Learn More

Are you getting the right information you need to make decisions?

Featured Insights from Darwin

Our Take Newsletter

Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

Learn More

Our Take Newsletter

Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Learn More

Our Take Newsletter

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Learn More

podcast

February 6, 2026

Podcast 199: A New Blueprint for Rural Health Care w/ Natalie L. Baggio, President, Corewell Health South

Listen in

podcast

January 23, 2026

Podcast 198: Standing Strong as an Independent Health System w/ Dr. Allen Smith & Dr. Sam Ash, South Shore Health

Listen in

podcast

January 8, 2026

Podcast 197: Making Health Care Costs Simple and Transparent w/ Mark Cuban, Co-Founder, Cost Plus Drugs

Listen in

podcast

December 19, 2025

Podcast 196: Physician Leadership in a New Era of Health Care w/ Dr. Sowmya Viswanathan, Baycare

Listen in

podcast

December 12, 2025

Podcast 195: Why Primary Care Is Under Strain w/ Dr. Greg Whisman, Chief Medical Officer, CareMore Health

Listen in

Explore All Content

Stay Aware. Stay Informed.

Subscribe to Our Take

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Explore Content

Our Objective Insights. Your Strategic Advantage.

Darwin Research Group delivers strategic intelligence and deep executive insights that guide health care leaders to make confident decisions. Our expert knowledge of the ever-evolving health care landscape gives you the perspective you need to stay ahead.

Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Providing insights for the most prominent leaders in health care.

We’re here to serve you.

Consulting & Strategic Counsel

Customer Intelligence, Data, & Profiles

Inside Access To Research & Data

Are you getting the right information you need to make decisions?

Featured Insights from Darwin

Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Podcast 199: A New Blueprint for Rural Health Care w/ Natalie L. Baggio, President, Corewell Health South

Podcast 198: Standing Strong as an Independent Health System w/ Dr. Allen Smith & Dr. Sam Ash, South Shore Health

Podcast 197: Making Health Care Costs Simple and Transparent w/ Mark Cuban, Co-Founder, Cost Plus Drugs

Podcast 196: Physician Leadership in a New Era of Health Care w/ Dr. Sowmya Viswanathan, Baycare

Podcast 195: Why Primary Care Is Under Strain w/ Dr. Greg Whisman, Chief Medical Officer, CareMore Health

Subscribe to Our Take

Podcast 199: A New Blueprint for Rural Health Care w/ Natalie L. Baggio, President, Corewell Health South

Podcast 198: Standing Strong as an Independent Health System w/ Dr. Allen Smith & Dr. Sam Ash, South Shore Health

Podcast 197: Making Health Care Costs Simple and Transparent w/ Mark Cuban, Co-Founder, Cost Plus Drugs

Services

Company